The rise of Viagra and its impact on the drug landscape presents a complex question for shareholders. While the early sales figures were impressive, the patent has ended, leading to a flood of copycat alternatives that are reducing earnings. Moreover, the market is facing challenges related to population trends and evolving healthcare policies, … Read More